Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZW 49

Drug Profile

ZW 49

Alternative Names: anti-HER2 x HER2 ADC - Zymeworks; ZW49

Latest Information Update: 15 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Oesophageal cancer; Solid tumours
  • Preclinical Gastric cancer

Most Recent Events

  • 14 Jan 2020 Interim efficacy and safety data from phase II trial in HER-2 expressing Cancers released by Zymeworks
  • 24 Jan 2019 Phase-I clinical trials in Breast cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV)
  • 24 Jan 2019 Phase-I clinical trials in Oesophageal cancer (Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top